جست‌وجوی استاد و پژوهشگر

Brent Pageمشاهده پروفایل

دانشیار

• Medicinal Chemistry
• Chemical Biology
• Drug Discovery and Development
• +۱۳ مورد دیگر

Brent Page is an Associate Professor (tenured) in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) and maintains a research group at the Karolinska Institute , Department of Oncology and Pathology. His dual affiliation underpins a trans-Atlantic program that integrates cutting-edge chemical biology with medicinal chemistry for anti-cancer drug discovery. Education & Training PhD in Chemistry – University of Toronto (2013) HBSc in Chemistry (Honours) – University of British Columbia (2008) CIHR Postdoctoral Fellow – Karolinska Institute, Sweden (2008–2016) Assistant Professor (non-independent) – Karolinska Institute, Department of Oncology-Pathology (2017–2021) Research Focus Dr. Page’s laboratory operates at the interface of medicinal chemistry and chemical biology , aiming to identify and optimize small-molecule inhibitors for proteins previously considered “undruggable.” Core targets include STAT3, CLIC3, NUDT5/15 and SRPK3 . The group employs cellular thermal shift assays , isothermal ligand-induced resolubilization (ILIRA) , and CeTEAM technologies to quantify target engagement and refine structure–activity relationships in physiologically relevant models of breast cancer, triple-negative breast cancer, leukemia and atopic diseases . Funding & Collaborations His program is supported by Canadian Institutes of Health Research (CIHR) and other national and international agencies. Dr. Page actively participates in UBC’s Accelerated Translational Opioid Research Cluster and welcomes interdisciplinary collaborations and undergraduate research involvement. Equity, Diversity & Inclusion Committed to fostering an inclusive environment, Dr. Page mandates EDI training for all lab members and actively encourages participation from equity-deserving groups.

Xin Liمشاهده پروفایل

استاد

• Plant Innate Immunity
• Molecular Mechanisms of Plant Defense
• Pathogen-Plant Interactions
• +۵ مورد دیگر

Dr. Xin Li is a Professor at the University of British Columbia (UBC), affiliated with the Michael Smith Laboratories and the Department of Botany. She holds a Tier 1 Canada Research Chair in Plant Immunity and leads research on plant innate immunity mechanisms, focusing on molecular pathways in Arabidopsis thaliana. Her work explores how plants defend against pathogens through gene regulation, protein interactions, and signal transduction. Education: BSc in Genetics from Fudan University (1989), PhD in Plant Pathology from Oklahoma State University (1995), postdoctoral training at Duke University (1996-1999). Prior to UBC, she was a Scientist at Maxygen, Inc. (1999-2001). Research spans biochemistry, genomics, and proteomics, with a focus on regulatory components of plant disease resistance. Key areas include NLR immune receptors, salicylic acid signaling, and translational strategies for sustainable agriculture. Lab members include PhD students (e.g., Paul Kapos, Kevin Ao), MSc students (e.g., Nanbing Zhang), and postdocs (e.g., Tongjun Sun). The Li Lab collaborates internationally, notably through the PRoTECT training program funded by NSERC and DFG. Notable awards include the Tier 1 CRC nomination (2022) and grants supporting the PRoTECT initiative. Her research has led to over 70 peer-reviewed publications, advancing understanding of plant immunity and its applications in crop protection.

David A. Hoodمشاهده پروفایل

استاد

• Cell Physiology
• Mitochondrial Biology
• Skeletal Muscle Physiology
• +۹ مورد دیگر

David A. Hood is a Full Professor and former Canada Research Chair in Cell Physiology (2003–2024) at York University, affiliated with the School of Kinesiology and Health Science. He is the Founding Director of the Muscle Health Research Centre (MHRC) and supervises graduate students in the Biology Graduate Program. Research Interests: His research focuses on mitochondrial biogenesis, turnover, and function in skeletal muscle. He investigates how exercise, aging, and muscle disuse affect mitochondrial health, with a particular interest in mitophagy, lysosomal function, and cellular signaling. His work spans human, animal, and cellular models, integrating physiological, biochemical, and molecular biology approaches. Recent Publication Trends: Recent publications emphasize transcriptional regulation (e.g., TFEB, TFE3, ATF4, p53), organelle crosstalk (mitochondria-lysosome interactions), and the role of exercise as 'mitochondrial medicine.' His lab explores therapeutic interventions like mitochondrial transplantation and nutrient signaling in muscle health. Scientific Awards: Canada Research Chair in Cell Physiology (2003–2024) Finalist for a prestigious national award Advising and Grants: Dr. Hood actively mentors graduate students and postdoctoral fellows. He has secured significant funding, including a $1 million CIHR grant to study mitochondria and lysosomes in muscle. His lab fosters interdisciplinary collaboration and contributes to major reviews in the field. Labs and Teams: He leads the Hood Lab at York University and co-founded the Muscle Health Research Centre (MHRC), a multidisciplinary hub promoting research on muscle function, exercise, and aging. The MHRC facilitates collaboration across departments and institutions.

Shadi Daliliمشاهده پروفایل

دانشیار

• Biologically Active Isatin Derivatives
• Hole Transport Materials (HTMs) for Perovskite Solar Cells
• Augmented Reality in Chemistry Education
• +۳ مورد دیگر

Shadi Dalili is an Associate Professor, Teaching Stream at the University of Toronto's Scarborough (UTSC) campus. He specializes in Chemistry Education and Organic Chemistry research. His roles include teaching undergraduate courses like Organic Chemistry I and mentoring students in directed research projects. Education: BSc, University of Tehran, Iran (1999) MSc, University of Toronto (2001) PhD, University of Toronto (2005) Research Interests: His work focuses on synthesizing biologically active isatin derivatives, developing hole transport materials (HTMs) for Perovskite solar cells, and advancing chemistry education through technologies like augmented reality (AR). Collaborations with Dr. Kagan Kerman and Dr. Meissam Norouzifar address renewable energy materials, while his work with Dr. Maryam Abdinejad led to the ARchemy app, supported by grants from the Centre for Teaching and Learning and ITIF. Publications: Key contributions span AR-based educational tools, organic synthesis methodologies, and drug discovery. Recent work highlights include studies on student perceptions of AR in chemistry and lab skills seminars. Grants & Collaboration: Received $20,000 in grants for ARchemy development and partnered with UofT’s MADlab. Research emphasizes bridging technology and education, with applications in molecular visualization and renewable energy materials. Labs/Teams: Lead the ARchemy project team and collaborates on Perovskite solar cell research, fostering interdisciplinary innovation.

Anand Krishnanمشاهده پروفایل

استادیار

• Nerve-tumor interface
• Nerve regeneration
• Cancer biology
• +۵ مورد دیگر

Dr. Anand Krishnan serves as Assistant Professor in the Department of Anatomy, Physiology and Pharmacology at the University of Saskatchewan's College of Medicine, where he leads research on nerve-tumor interfaces and neural macrophage biology. His work bridges neuroscience and oncology to identify therapeutic targets for cancer and neurodegenerative disorders. Education: Postdoctoral Fellow, Division of Neurology, University of Alberta, Canada Postdoctoral Fellow, Clinical Neurosciences, University of Calgary, Canada PhD in Biotechnology (Cancer Biology), Rajiv Gandhi Centre for Biotechnology, India Master of Pharmacy (Pharmacology), Manipal University, India Pharma R&D Experience: Orchid Chemicals and Pharmaceuticals Limited; Alembic Pharmaceuticals Limited Dr. Krishnan's research program investigates two core areas: molecular mapping of tumor-nerve interfaces to uncover novel therapeutic targets, and defining the roles of self-renewing resident macrophages in nervous system homeostasis and disease. His lab employs proteomics, murine models, and in vitro neuronal cultures to explore how tumors and nerves mutually support growth through neural invasion and autonomic signaling. Analysis of his 2020-2024 publications reveals consistent focus on neuro-oncology mechanisms, particularly peripheral nerve regeneration pathways (Myc interactome, growth-primed DRG), tumor-nerve crosstalk (sympathetic signaling in prostate cancer), and neurodegenerative targets (MANF). Key methodologies include comparative proteomics, molecular mapping, and drug repurposing screens. Research Funding: Natural Sciences and Engineering Research Council (NSERC) Cancer Research Society (CRS) CIHR Institute of Cancer Research Breast Cancer Society of Canada (BCSC) Prostate Cancer Fight Foundation (PCFF) & Ride for Dad Saskatchewan Health Research Foundation (SHRF) College of Medicine Research Award (CoMRAD) CoMBRIDGE Fund Start-up Research Fund Based at Saskatoon City Hospital within the Cameco MS Neuroscience Research Centre, the Krishnan Lab trains students supported by NSERC USRA, Dean's project fellowships, OVDR Biomedical research fellowships, and Mitacs awards. The lab's strategic location adjacent to the Meewasin Valley provides collaborative opportunities for translational neuroscience research focused on nerve regeneration and cancer therapeutics.

• Progranulin research
• Neuroprotection
• Tissue repair
• +۴ مورد دیگر

Andrew Bateman, PhD is a Senior Scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) at the Glen site, where he leads research in the Metabolic Disorders and Complications Program within the Centre for Translational Biology. He holds a professorship in the Department of Medicine, Faculty of Medicine and Health Sciences at McGill University, with specific affiliation to the Division of Endocrinology at the McGill University Health Centre. Dr. Bateman's research primarily focuses on progranulin, a protein that plays crucial roles in cell communication, neuroprotection, tissue repair, and cancer progression. His work has demonstrated that progranulin instructs nearby cells to divide and move, inhibits cell death caused by challenges such as starvation or chemotherapeutic drugs, and is essential for keeping nerve cells alive. Notably, his research has shown that losing half of the brain's progranulin levels through mutation causes frontotemporal dementia, a devastating degenerative brain disease. His laboratory also investigates how progranulin is overexpressed in many cancers, rendering cancer cells more aggressive, and how blocking progranulin may serve as a route to cancer therapy. Additionally, his work explores progranulin's role in reducing inflammation and promoting wound repair, including angiogenesis, which has potential applications for people suffering from chronic wounds. Analysis of Dr. Bateman's publication record reveals a consistent focus on progranulin across multiple disciplines including neuroscience, molecular biology, oncology, and vascular biology. His research spans from fundamental protein structure and evolution to clinical applications in neurodegenerative diseases and cancer. A notable trend in his work is the exploration of progranulin's dual role in both neuroprotection and cancer progression, highlighting the complex nature of this regulatory protein. His research has evolved from early work on corticostatic peptides and the immune-hypothalamic-pituitary-adrenal axis to his current specialized focus on progranulin's multifaceted biological functions. Dr. Bateman has made significant contributions to understanding the role of progranulin in various physiological and pathological processes. His work has implications for developing therapeutic approaches for neurodegenerative diseases, cancer treatment, and wound healing. He has established himself as a leading researcher in the field of progranulin biology, with numerous publications in high-impact journals spanning several decades of research.

Caroline Schild-Poulterمشاهده پروفایل

استاد

• Molecular Biology
• Genetics
• DNA Repair
• +۳ مورد دیگر

Caroline Schild-Poulter is a Professor and Scientist at the Robarts Research Institute, affiliated with the Schulich School of Medicine & Dentistry at Western University in London, Ontario, Canada. She leads research in the Molecular Medicine department, specifically within the Vascular and Brain Health Group, focusing on DNA damage response mechanisms and their implications in cancer development. Education: Undergraduate in Biology at the University of Lausanne, Switzerland (Major in Molecular Biology) Master's and PhD at the University of Lausanne (Topic: Mechanisms regulating gene expression) PhD training included a 2-year stage at the National Institutes of Health, Bethesda, USA Dr. Schild-Poulter's research program centers on DNA repair/signaling pathways activated by double-stranded DNA breaks, one of the most dangerous forms of DNA damage. Her work specifically investigates how DNA gets repaired and how apoptosis is activated when repair is not completed. Her research has significant implications for understanding cancer development, stroke, and aging processes. She has made notable contributions to understanding the roles of RanBPM in controlling apoptosis in response to DNA damage and how the DNA repair factor Ku functions to repair and signal from double-stranded DNA breaks. Analysis of her publication record shows consistent focus on DNA repair mechanisms, with recent work expanding into RNA-mediated immunity and protein degradation pathways. Scientific Awards: Natural Sciences and Engineering Research Council Canada (NSERC) Discovery Accelerator Award (DAS) Post-doctoral Fellowship, Medical Research Council of Canada and the Arthritis Society Post-doctoral Fellowship, Association pour la Recherche sur le Cancer (France) Fellowship, Centre National de la Recherche Scientifique (France) Post-doctoral Fellowship, Swiss National Science Foundation (Switzerland) Dr. Schild-Poulter has received significant research funding through competitive grants, including the prestigious NSERC Discovery Accelerator Award which supports her innovative work in DNA repair mechanisms. Her research program has led to numerous publications in high-impact journals and has contributed significantly to our understanding of genomic instability and cancer development. While specific students aren't listed in the available information, her position as a Professor suggests she mentors graduate students and postdoctoral fellows in her laboratory, contributing to the next generation of molecular biologists and cancer researchers. Dr. Schild-Poulter is a key member of the Molecular Medicine research group at Robarts Research Institute, where she maintains an active laboratory investigating DNA damage response pathways. Her work bridges basic molecular mechanisms with potential clinical applications in cancer treatment and prevention, particularly focusing on the critical balance between DNA repair and programmed cell death that prevents malignant transformation.

• Medical Physics
• Radiation Oncology
• Quantitative Ultrasound
• +۵ مورد دیگر

Roxana Vlad is an Assistant Professor in the Interdisciplinary Science program within the Faculty of Science at McMaster University, and also serves as a Medical Physicist at Juravinski Hospital and Cancer Centre. Her work bridges academic research with clinical applications in radiation physics and medical imaging, maintaining active scholarly output from 1999 through 2025. Dr. Vlad's research focuses on medical physics applications, particularly in radiation oncology and quantitative ultrasound. Her work centers on developing and applying ultrasound techniques for monitoring cancer treatment responses, especially radiation therapy. She has pioneered methods for using high-frequency ultrasound spectroscopy to detect cellular changes during apoptosis and other cell death processes, enabling real-time monitoring of treatment efficacy. Her research spans from basic science investigations of cellular changes to clinical applications in cancer treatment monitoring, with publications mapped across 554 scientific subdisciplines. Analysis of Dr. Vlad's publication record reveals a consistent progression from fundamental studies of cellular changes during radiation therapy to increasingly sophisticated clinical applications. Key themes include the development of ultrasound spectroscopy for detecting DNA damage, 3D ultrasound reconstruction techniques, and integration with other imaging modalities like MRI for comprehensive treatment assessment. Her recent work has expanded to include clinical implementation of new radiation therapy technologies (2022 publications on Varian Halcyon systems) and even mental health assessment in medical education (2025 publication on Romanian medical students). Referenced in 19 patents for some publications 79 readers on Mendeley for key works Strong presence in Radiology (40.7% of activity), Radiation Therapy (18.5%), and Instrumentation (14.8%) As an educator, Dr. Vlad teaches courses including Radiation Oncology Physics II (MEDPHYS 788), Clinical Applications of Physics in Medicine (MEDPHYS 4T03), and Integrated Science I (ISCI 1A24A). She actively seeks to involve students in research that "can bring innovations into the clinical environment of radiation physics." Her clinical role at Juravinski Hospital and Cancer Centre directly informs her research direction and ensures practical relevance to patient care.

Andrew Beharryمشاهده پروفایل

دانشیار

• Biological Chemistry
• Organic Chemistry
• Cancer Biology
• +۳ مورد دیگر

Andrew Beharry is an Associate Professor in the Department of Chemical & Physical Sciences at the University of Toronto Mississauga. His research focuses on developing small molecule probes for cancer biology, including fluorescent chemosensors for drug resistance assessment and activatable photosensitizers for photodynamic therapy (PDT). His lab integrates chemical synthesis, biochemical assays, and in vivo models to create diagnostic tools and treatment platforms that address limitations of conventional cancer therapies. Education & Training: B.Sc. (Honours) in Chemistry and Biology, York University (2006) Ph.D. in Chemistry, University of Toronto (2012) Postdoctoral Fellow, Stanford University (2013–2016), funded by the Human Frontier Science Program Research Interests: Beharry’s lab bridges chemistry and biology to tackle cancer challenges. Key areas include: Fluorescent Chemosensors: Rapid, accurate assays for anticancer drug resistance mechanisms (e.g., DNA repair enzymes, cell death pathways). Activatable Photosensitizers: Cancer-selective PDT agents that enable real-time imaging and therapy via biomarker activation. Fluorescence-Guided Therapies: Combining PDT with surgical imaging to reduce cancer recurrence. Achievements & Funding: Recipient of NSERC Discovery Grant (2017–2022), Connaught New Researcher Award (2017–2019), and Brain Tumour Foundation of Canada Grant (2021–2023). Over 50 publications in high-impact journals like J. Am. Chem. Soc. , ACS Med. Chem. Lett. , and Biochemistry . Labs & Teams: The Beharry Lab collaborates with institutions globally, focusing on translational research from bench to clinic. Current projects include enzyme-activatable prodrugs and theranostic agents for precision oncology.

Evelyn Yimمشاهده پروفایل

استاد

• Biomaterials
• Tissue Engineering
• Nanopatterning
• +۳ مورد دیگر

Evelyn Yim is a Professor and Canada Research Chair in Nanomaterials for Regenerative Medicine (Tier 1) at the University of Waterloo. Her research focuses on biomaterials, tissue engineering, and nanotopography to regulate stem cell behavior. Her work spans applications in corneal regeneration, vascular graft engineering, and neural differentiation. Her research interests include the development of biomaterial-based strategies for corneal endothelial cell expansion, functional wound dressings, and enzyme-responsive hydrogels. She also investigates the effects of surface topography on vascular and neuronal cells, aiming to create bio-inspired materials that mimic natural environments. Key contributions include advancements in biomaterials for vascular compliance matching, droplet microfluidics for cell encapsulation, and enzyme-triggered drug delivery systems. Her work bridges material science and clinical applications, with a focus on translational regenerative medicine. Dr. Yim’s research has produced over 50 peer-reviewed articles since 2020, addressing topics from nanotopography-driven stem cell differentiation to hemocompatible vascular grafts. Her lab (YimLab) is a leader in biomaterials innovation for medical applications.

• Apoptosis
• Renal System
• Transplantation
• +۹ مورد دیگر

Marie-Josée Hébert is a Full Professor at the Université de Montréal's Faculty of Medicine, Department of Medicine, and holds the Shire Chair in Nephrology, Transplantation, and Renal Regeneration. She is a researcher at the CRCHUM and co-director of the Canadian National Transplant Research Program (CNTRP). Her research focuses on vascular injury mechanisms in transplantation, identifying biomarkers like LG3 and anti-LG3 antibodies critical for understanding allograft rejection and fibrosis. She has led over 100 research projects funded by CIHR, FRQS, and other agencies, securing millions in grants. Education: MD from Université de Montréal, postdoctoral training at Harvard. Awards: Includes the 2016 Kidney Foundation Medal and CRCHUM's Scientific Contribution Award. Key Roles: Director of Transplant Programs, leader in interdisciplinary research networks, and advocate for translational medicine. Research Interests: Molecular mechanisms of cell death, paracrine signaling in fibrogenesis, immunosuppressive therapies, and kidney transplantation outcomes. Her work bridges basic science and clinical applications, emphasizing patient-centered discoveries. Grants & Projects: Over 50 funded projects since 2001, including Apogée Canada initiatives ($30M+), vascular injury studies, and collaborations on AI-driven healthcare. Lab/Teams: CRCHUM Research Center, CNTRP, and Nephrology Research Consortium with patient biobank.

• Proteomics
• Structural Biology
• Parkinson's Disease
• +۷ مورد دیگر

Jean-François Trempe is an Associate Professor in the Department of Pharmacology and Therapeutics at McGill University's Faculty of Medicine and Health Sciences. He serves as a Researcher at the McGill University Health Centre Research Institute (IR-MUHC) at the Glen site, where he is affiliated with the Program in Brain Repair and Integrative Neuroscience and the Center for Translational Biology. Dr. Trempe's research program focuses on the structural and pharmacological aspects of proteins involved in Parkinson's disease, particularly Parkin and PINK1. His laboratory investigates how mutations in these proteins lead to early-onset familial Parkinson's disease through disruptions in mitochondrial quality control processes essential for neuronal survival. Using techniques including proteomics, structural biology, crystallography, NMR, and mass spectrometry, his team has made significant contributions to understanding the activation mechanism of Parkin by PINK1 and how these proteins function in mitochondrial maintenance. Current research directions include leveraging 3D structural information to design therapeutic strategies for pathogenic Parkin mutations, exploring how PINK1 detects damaged mitochondria, and investigating the role of Parkin/PINK1 in clearing mitochondrial damage using stem cell-derived neurons and animal models. Dr. Trempe's publication record demonstrates a strong interdisciplinary approach spanning structural biology, biochemistry, and neuroscience. His most recent work includes discoveries regarding molecular glue compounds that activate Parkin, the role of the PINK1-TOM-TIM23 supercomplex in mitochondrial import stress, and connections between Parkin activation and tumor progression. His highly cited 2014 Nature paper demonstrating that ubiquitin is phosphorylated by PINK1 to activate parkin represents a landmark contribution to the field. His research has significant translational implications for developing targeted therapeutic interventions for Parkinson's disease and understanding fundamental cellular quality control mechanisms. Dr. Trempe maintains extensive collaborations within McGill University and with international research teams, particularly with Dr. Edward Fon's laboratory, as evidenced by numerous co-authored publications across multiple high-impact journals.

Fouad Daayfمشاهده پروفایل

استاد

• Molecular Plant-Pathogen Interactions
• Plant Defense Mechanisms
• Biocontrol Strategies
• +۴ مورد دیگر

Dr. Fouad Daayf is a Professor in the Department of Plant Science at the University of Manitoba’s Faculty of Agricultural and Food Sciences. His research focuses on molecular and biochemical interactions between plants and pathogens, including defense suppression mechanisms, biocontrol strategies using plant extracts and beneficial microbes, and detection biology of soilborne/foliar pathogens. Education: PhD in Plant Pathology (Montpellier University, France), Doctorat-d’État in Plant Biotechnology (Cadi Ayyad University, Morocco), MSc in Agronomic Sciences (University of Manitoba), BSc in Plant Biology (Cadi Ayyad University). He teaches courses like PLNT4580 Molecular Plant-Microbe Interactions and PLNT4570 Research Methods in Plant Pathology . His current projects include NSERC-Discovery on pathogen adaptation, S-CAP for potato disease management, and CAP-Barley Cluster for pathogen variation studies. He serves on the Canadian Plant Health Council and chairs the CPS Manitoba Regional Section. Scientific awards include the 2021 Canadian Phytopathological Society Outstanding Research Award and multiple University of Manitoba Merit Awards for research and service. His lab has trained numerous PhD/MSc students and postdocs studying plant defense mechanisms against pathogens like Phytophthora infestans and Verticillium dahliae .

Lucy Marzbanمشاهده پروفایل

دانشیار

• Beta-cell Death
• Islet Amyloid
• Diabetes Pathogenesis
• +۲ مورد دیگر

Dr. Lucy Marzban is Associate Professor at the University of Manitoba College of Pharmacy. Her research program focuses on understanding β-cell dysfunction and death in diabetes, particularly mechanisms of islet amyloid toxicity. She investigates molecular pathways to develop therapies preventing diabetes onset and improving islet transplant survival. Dr. Marzban holds a Doctor of Medical Laboratory Science (University of Toronto), Ph.D. (University of British Columbia), and completed postdoctoral fellowships at UBC and University of Geneva. Her work bridges molecular pharmacology and clinical applications in diabetes management.

Thomas J. Velenosiمشاهده پروفایل

استادیار

• Pharmacometabolomics
• Pharmacology
• Metabolomics
• +۷ مورد دیگر

Thomas J. Velenosi is an Assistant Professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia. He received his PhD in pharmacology and toxicology from Western University and completed his postdoctoral fellowship at the National Cancer Institute (National Institutes of Health). His research focuses on the intersection of pharmacology and metabolomics, particularly in cancer therapy and biomarker discovery. Institution: University of British Columbia Faculty: Faculty of Pharmaceutical Sciences Academic Rank: Assistant Professor Dr. Velenosi's research interests center around pharmacometabolomics, metabolomics, lipidomics, mass spectrometry, cancer biology, stable isotope tracing, and bioinformatics. His lab applies advanced analytical techniques to study drug treatment response and toxicity during cancer therapy, with a particular focus on identifying and characterizing metabolic biomarkers. His approach combines highly translational cancer models with computational methods to improve biomarker identification and clinical validation. The Velenosi lab's research focuses on two main areas: 1) developing computational methods for improving mass spectrometry-based metabolomics, lipidomics and stable isotope tracing, and 2) applying these techniques to cutting-edge cancer models to identify and characterize metabolic biomarkers and therapeutic targets. His work aims to bridge the gap between biomarker identification and clinical validation to facilitate personalized therapy for cancer patients. His research has resulted in numerous publications in high-impact journals, with a focus on cancer metabolism, kidney function biomarkers, and metabolic reprogramming. The most recent publications (2022-2025) show a strong trend toward precision medicine applications, particularly in triple-negative breast cancer, with emphasis on polyamine metabolism and biomarker discovery for treatment response prediction. Postdoctoral Fellowship, Canadian Institutes of Health Research, 2018 Canada Graduate Scholarship - Doctoral (CGS-D) Award, Natural Sciences and Engineering Research Council of Canada, 2012 Dr. Velenosi actively supervises graduate students in the Pharmaceutical Sciences and Bioinformatics programs, training them in state-of-the-art mass spectrometry, molecular biology, tissue culture, and animal cancer models. His lab utilizes highly controlled patient-derived xenograft models to identify and characterize metabolic biomarkers of drug effectiveness. The Velenosi lab is currently accepting applications for MSc and PhD students interested in studying metabolic biomarkers of drug response in cancer. The lab maintains a collaborative environment with regular social events, as evidenced by their summer pizza outings and holiday parties, fostering a strong team dynamic focused on advancing precision medicine for cancer treatment through metabolomics research.